MassBiologics is dedicated to the development of novel biologics for the treatment of diseases of public health importance. Our teams of scientists have the capabilities to move an investigational product from initial discovery, through process development and manufacturing and into early phase clinical trials. Over the past 10 years, MassBiologics, with or without partnerships, has developed human monoclonal antibodies targeted to infectious diseases: Clostridium difficile infection, rabies, severe acute respiratory syndrome (SARS), and hepatitis C (HCV) disease. In addition, MassBiologics has developed human monoclonal antibodies directed against human superoxide dismutase-1 (SOD-1), which may ultimately yield a novel therapy for the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). The Research teams at MassBiologics are focused on identifying new antibody targets for clinical development through in-house basic research as well as active collaborations with both academic and industry investigators.
For a list of faculty at MassBiologics click here.